Science-driven and focused
on developing the next generation of immuno-oncology gene and cell therapies,
Ziopharm has two distinct clinically advanced paths to stimulate, tune, and control the
body’s immune response to fight blood cancers and solid tumors.
“Our focus here at Ziopharm is to reestablish the immune system and allow the body’s own defenses to destroy tumors.”
Sleeping Beauty is one of the most clinically advanced non-viral cell therapy platforms that genetically modifies T cells to express CAR or TCR. This technology enables a new, scalable approach to manufacturing cell therapy products called point-of-care or POC manufacturing, and we believe it will produce these therapies in a fraction of the time and cost compared to what’s currently available.
Checkpoint inhibitors and combination therapy
Based on microscopy of tumor biopsies, IL-12 appears to upregulate multiple checkpoint inhibitors within the tumor microenvironment, suggesting IL-12 — in addition to having potential as a single-agent therapy — is well suited to combine with immune checkpoint inhibitors.